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Abstract. In the present study, the tetracycline-off and Cre/loxP 
systems were combined to gain temporal and spatial control of 
transgene expression. Mice were generated that carried three 
transgenes: Tie2-tTA, tet-O-Cre and either the ZEG or ZAP 
reporter. Tie2-tTA directs expression of tetracycline-controlled 
transactivator (tTA) in endothelial and hematopoietic cells 
under the control of the Tie2 promoter. Tet-O-Cre produces 
Cre recombinase from a minimal promoter containing the 
tet-operator (tetO). ZEG or ZAP contains a strong promoter and 
a loxP‑flanked stop sequence, followed by an enhanced green 
fluorescence protein (EGFP) or human placental alkaline phos-
phatase (hPLAP) reporter. In the presence of tetracycline, the 
tTA transactivator produced by Tie-2-tTA is disabled and Cre 
is not expressed. In the absence of tetracycline, the tTA binds 
tet-O-Cre to drive the expression of Cre, which recombines the 
loxP sites of the ZEG or ZAP transgene and results in reporter 
gene expression. In the present study, the expression of the ZEG 
or ZAP reporter genes in embryos and adult animals with and 
without tetracycline treatment was examined. In the presence of 
tetracycline, no reporter gene expression was observed. When 
tetracycline was withdrawn, Cre excision was activated and the 
reporter genes were detected in endothelial and hematopoietic 
cells. These results demonstrate that this system may be used to 
bypass embryonic lethality and access adult phenotypes.
Introduction
The circulatory system is the first functional system formed 
during mammalian embryogenesis, beginning with the 
aggregation of hemangioblasts, the common precursors of 
endothelial and hematopoietic cells, shortly following gastru-
lation. The hemangioblasts differentiate into several distinct 
cell lineages that form the network of blood vessels, the heart, 
circulating blood cells and supporting tissues. A number of 
molecules and signal transduction pathways are temporally 
and quantitatively regulated to maintain normal cardiovascular 
development (1,2). These include vascular endothelial growth 
factor (VEGF), basic fibroblast growth factor (bFGF), the 
angiopoietins/Tie pathway, the ephrins/Eph pathway and the 
DSL/Notch pathway. All of these pathways have been studied 
in vivo using traditional knockout, knock‑in and transgenic 
methods. In the majority of cases, these gene mutations induce 
embryonic lethality between E9.5 to E11.5 (3-5). However, 
the embryonic lethal phenotypes are similar and suggest 
that disruption to any of these pathways results in defects in 
the remodeling and maturation of the vasculature (6,7). The 
embryonic lethal phenotypes hinder the investigation of the 
function of these genes in later development, including possible 
roles in the determination of vessel identity, hematopoiesis, 
endothelial-mesenchymal transition and pericyte recruitment.
A number of techniques have been developed to achieve cell 
type-/tissue‑specific transgene expression. The first established 
inducible system was the lac repressor system regulated by 
isopropyl-β-D-thiogalactopyranoside (IPTG) (8,9). Currently, 
the Cre/loxP and tetracycline systems are the most widely 
used systems to control gene expression. Cre recombinase is a 
bacteriophage enzyme that recognizes two 34-base-pair loxP 
sites and excises the DNA between them (10,11). Conditional 
gene deletion and expression strategies have been developed by 
placing loxP sites around an essential part of a gene of interest 
or separating an ectopic promoter from the coding region of a 
gene by loxP‑flanked stop sequences (12‑14). In these configu-
rations, the gene alteration is silent prior to the excision of 
the loxP sites. Following the introduction of Cre recombinase 
under a tissue‑specific promoter, the loxP‑flanked sequence is 
excised and gene inactivation or transgene expression occurs 
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specifically in the tissues where Cre is expressed. While the 
Cre/loxP system provides spatial control of gene alteration, the 
tetracycline-inducible system provides temporal regulation. 
Under this system, a fusion protein composed of the VP16 
transactivator and either the tetracycline repressor (tTA) or 
reversed tetracycline repressor (rtTA) can be inhibited (tet-off) 
or activated (tet-on) by tetracycline, respectively (15,16). 
Therefore, the addition or withdrawal of tetracycline controls 
the activity of the transactivator, which then regulates the 
expression of a given gene from a promoter containing the 
tet‑operator (tetO) sequences.
In the present study, a strategy was developed in which 
the Cre/loxP and tet-off systems were combined to allow 
for spatial and temporal regulation of transgene expression 
in vivo. In this system, three transgenes are utilized. The first 
transgene drives the expression of a tetracycline-controlled 
transactivator (tTA) under the control of the Tie2 promoter, 
which allows selective transgene expression only in endothelial 
and hematopoietic cells. The second transgene expresses the 
Cre recombinase gene from a minimal promoter containing 
tet‑operator (tetO) sequences (17). The third transgene is the 
ZEG or ZAP reporter, which has a strong global promoter 
separated from an enhanced green fluorescence protein 
(EGFP) or human placental alkaline phosphatase (hPLAP) 
reporter gene by a loxP‑flanked stop sequence. The stop 
sequence contains a lacZ-neomycin resistance fusion (β-geo) 
gene with translation and transcription stops (13,18). With 
the combination of these transgenes, Cre expression does 
not occur in the presence of tetracycline and consequently 
the reporter genes are not expressed. At any point during 
embryonic development or adulthood, Cre expression can be 
activated through the removal of tetracycline, leading to Cre 
excision and expression of the reporter genes.
The advantage of combining the tetracycline-inducible and 
Cre/loxP systems is that once Cre is activated, it will excise 
the target transgene and make a permanent genetic alteration. 
The reporter gene will be expressed in the Cre-expressing 
cells and in all the progeny of that cell, even if the inducing 
condition is removed. Thus a limited number of cells can be 
marked for reporter gene expression for applications such as 
mosaic analysis. This also represents a valuable approach to 
the modelling of cancer, where a limited number of cells in an 
organ undergo the critical oncogenic mutations and those cells 
then go on to form a tumor. In developing cancer treatments 
and testing them, this type of model may be useful to ascertain 
the effectiveness of a treatment at eliminating the cancerous 
cells. By contrast, in systems where only an inducing agent, 
for example tetracycline or tamoxifen, is used, expression of 
the target transgene requires the continuous application of 
the inducing condition, and that continuous application leads 
to an endless supply of oncogene expressing cells; thus, it 
is difficult to determine whether a treatment eliminates the 
oncogenic cells.
Materials and methods
Transgenic mice. The Tie2-tTA mice (provided by Dr Andras 
Nagy; Lunenfeld-Tanenbaum Research Institute, Toronto, 
Canada) express the tTA in endothelial and hematopoietic 
cells under the control of a 2.1 kb Tie2 promoter fragment 
and a 10 kb fragment carrying an enhancer present in the first 
intron of Tie-2 (19). The tet-O-Cre mice (also provided by Dr 
Andras Nagy), carry the Cre coding sequence downstream of 
a minimal cytomegalovirus (CMV) promoter and tetracycline 
operator. ZEG and ZAP reporter mice were constructed in our 
laboratory, as previously described (13,18). The mice have a 
strong CMV-enhancer/chicken β-actin promoter followed by 
a loxP‑flanked stop sequence consisting of a lacZ-neomycin 
resistance fusion (β-geo™) gene and three polyadenylation 
sequences. The loxP‑flanked stop is followed by hPLAP in ZAP 
mice and EGFP in ZEG mice. The Animal Care Committee of 
Sunnybrook Research Institute (Toronto, Canada) approved all 
animal experiments carried out in the present study.
Mouse genotyping. The ZEG and ZAP mice were genotyped 
by lacZ staining of ear biopsies as previously described (13,18). 
Tie2-tTA and tet-O-Cre mice were genotyped using PCR 
using genomic DNA isolated from mouse ear biopsies. 
Genomic DNA was extracted from the biopsies using a 
REDExtract-N-Amp™ Tissue PCR kit (Sigma‑Aldrich, 
St. Louis, MO, USA) following the manufacturer's instruc-
tions. For each sample analyzed, ~100 ng of DNA was 
amplified using a S1000™ Thermal Cycler (Bio-Rad, Hercules, 
CA, USA). The primers used were as follows: Cre forward, 
5'-AATTTACTGACC GTACACCA-3'; Cre reverse, 
5'-CGCCGCATAACCAGT GAAAC-3'; tTA forward, 
5'-CTCACTTTTGCCCTTTAG AA-3'; tTA reverse, 
5'-GCTGTACGCGGACCCACTTT-3'. The thermal-cycle 
program was as follows: 94˚C for 5 min (1 cycle), 94˚C for 
30 min, 55˚C for 1 min, 72˚C for 1 min (30 cycles), 72˚C for 
5 min (1 cycle).
Alkaline phosphatase (AP) staining. AP staining was 
performed as previously described (14). Briefly, pregnant 
females were euthanized by cervical dislocation and the uterus 
was removed and washed in cold phosphate-buffered saline 
(PBS). Embryos were dissected out of the uterus and parts 
of the yolk sacs were removed for genotyping, whereas the 
embryos were fixed in lacZ fix solution (0.2% glutaraldehyde, 
50 mM EGTA, pH 7.3, 100 mM MgCl2 in 100 mM sodium phos-
phate, 0.02% NP‑40 and 0.01% sodium deoxycholate, pH 7.3) 
for 15 min. For the cross sections, the slides were prepared 
as described below. Embryos or slides were then washed in 
PBS and endogenous APs were inactivated by incubation in 
PBS at 70‑75˚C for 30 min. Following washing in AP buffer 
(100 mM Tris-HCl, pH 9.5, 100 mM NaCl, 10 mM MgCl2) for 
10 min, the samples were stained with AP staining solution 
[(100 mM Tris-HCl, pH 9.5, 100 mM NaCl, 50 mM MgCl2, 
0.01% sodium deoxycholate, 0.02% NP‑40, 337 mg/ml nitro-
blue tetrazolium salt (Roche Diagnostics, Basel, Switzerland), 
and 175 mg/ml 5-bromo-4-chloro-3-indolyl phosphate, tolu-
idinium salt (Roche Diagnostics)]. The staining reaction was 
allowed to proceed for 10-30 min at room temperature. The 
samples were then washed in PBS and stored at 4˚C.
Immunohistochemistry. The tissue samples were dissected in 
cold PBS and fixed in 4% paraformaldehyde overnight, washed 
in PBS three times for 15 min and cryoprotected in 15% sucrose 
in PBS for 1 h at 4˚C followed by 30% sucrose in PBS over-
night at 4˚C. The samples were then incubated in Tissue‑Tek 
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OCT (Sakura Finetek USA Inc, Torrance, CA, USA) at 4˚C for 
4 h prior to embedding in OCT over dry ice. The frozen blocks 
were cryosectioned at 7 µm, placed onto L-polylysine-coated 
slides (Thermo Fisher Scientific, Waltham, MA, USA), and 
dried for 1-4 h at room temperature prior to storage at -20˚C. 
For immunostaining, the sections were quenched sequentially 
in 3% hydrogen peroxide and blocked with diluted 10% normal 
goat serum (for EGFP) or 5% normal rabbit serum [for platelet-
endothelial cell adhesion molecule (PECAM)]. Slides were 
then incubated at 4˚C overnight with the primary antibodies, 
which comprised anti-PECAM-1 monoclonal antibody (1:100; 
BD Pharmingen, San Diego, CA, USA) and anti‑GFP mono-
clonal (3E6) antibody (1:2,000; Molecular Probes, Eugene, 
OR, USA). The next day, the slides were exposed for 30 min to 
biotinylated secondary antibodies including rabbit anti-rat or 
goat anti-rabbit (1:200; Vector Laboratories, Inc., Burlingame, 
CA, USA). The peroxidase activities were visualized using 
streptavidin-horseradish peroxidase together with the diami-
nobenzidine detection system (Vector Laboratories, Inc.). 
Finally, slides were washed and counterstained with hema-
toxylin (Surgipath; Leica Microsystems, Wetzlar, Germany). 
Images of slides were captured by photography using a Leica 
DFC300 camera with Leica FireCam 120 program.
Flow cytometry. Single cell suspensions were prepared by 
dissociating tissues in fluorescence-activated cell sorting 
(FACS) buffer (PBS with Ca2+/Mg2+, 0.1% NaN3 and 5% FCS) 
and filtering through a 40‑µm cell filter. Spleen samples were 
treated with freshly prepared red blood cell lysis buffer (9:1 
mix of 0.83% NH4Cl and 1 m Tris‑HCl pH 7.65) and refiltered. 
Samples were resuspended in FACS buffer supplemented with 
1 mg/ml of propidium iodide. Appropriate isotype controls 
were included with each experiment. Fluorescence of EGFP 
was detected on the FL‑1 channel of a FACSCalibur instrument 
(BD Biosciences, Franklin Lakes, NJ, USA). Results were then 
analyzed using FlowJo (TreeStar Inc., San Carlos, CA, USA).
Results
Tie2‑tTA/tet‑O‑Cre transgene combination activates Cre 
excision in endothelial and hematopoietic cells. The effi-
ciency of Cre excision activated by the Tie2-tTA/tet-O-Cre 
transgene combination was analyzed by maintaining mice in 
the absence of tetracycline (Fig. 1B). ZAP was initially used 
as the reporter mouse line (13,20). Tet-O-Cre male mice were 
bred with Tie2-tTA/ZAP female mice and embryos were 
collected at E8.5, 9.5, 10.5 and 11.5. The embryos and yolk 
sacs of the entire litter were stained for AP activity. Part of 
the yolk sac was also genotyped by PCR to identify triple 
transgenic embryos. At E8.5, no staining was observed in 
the Tie2-tTA/tet-O-Cre/ZAP embryos and yolk sac. At E9.5, 
a substantial number of cells positively stained for AP were 
observed in the yolk sac and the heart (data not shown). At 
E10.5, the majority of the yolk sac stained for AP (Fig. 2B) 
and AP positive vessels were also observed within the cranium 
and somites (Fig. 2B). At E11.5 the yolk sac strongly stained 
for AP, while the vessels in the embryos were already deep 
beneath the tissue at this stage and were not visible clearly.
The embryos were frozen and transversely sectioned 
to observe the AP staining within the embryo. Virtually 
all endothelial cells of Tie2-tTA/tet-O-Cre/ZAP embryos 
in sections showed positive AP staining at E11.5 (Fig. 2C 
and D). The endogenous Tie2 receptor is expressed not only 
in endothelial cells, but also in hematopoietic cells, which 
aggregate and adhere to the endothelial cells of arteries (21). 
It was observed that a fraction of hematopoietic cells were 
positively stained for AP on E11.5 within the arteries, whereas 
hematopoietic cells in the veins were not stained (Fig. 2C 
and D). Similar observations have been previously described 
for Tie2-Cre/CAG-CAT-Z embryos (22).
While AP expression of Tie2-tTA/tet-O-Cre/ZAP 
embryos was restricted at E8.5 and E9.5, Tek‑tTA/Tet-O-LacZ 
embryos showed lacZ expression beginning at E8.5 (Tek is 
a Tie2 promoter) (23). This supports previous observations 
that Cre excision and resultant reporter gene expression 
may not occur until 1-2 days after Cre expression is initi-
ated (20).
Figure 1. Tetracycline‑Cre inducible system. (A) Tie2‑tTA/ZEG or 
Tie2-tTA/ZAP mice were crossed with tet-O-Cre mice. In the presence of tet-
racycline, the triple transgenic embryos (Tie2-tTA/tet-O-Cre/ZEG) express 
tTA in endothelial cells and hematopoietic cells, but the tetracycline-bound 
tTA does not bind the tet operator. (B) When tetracycline is withdrawn, the 
tTA binds to the tet operator, which induces the activation of Cre expres-
sion and results in the deletion of the STOP sequence and expression of the 
reporter [enhanced green fluorescence protein (EGFP) or human placental 
alkaline phosphatase (hPLAP)].
  A
  B
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ZEG reporter mice were used to analyze the expression 
within adult tissues since the second reporter EGFP may be 
visualized in live animals and cells either directly or using 
flow cytometry (18,20). Tie2‑tTA/ZEG mice were bred with 
tet-O-Cre mice and triple transgenic Tie2-tTA/tet-O-Cre/ZEG 
pups were obtained, which displayed light green fluorescence 
at birth, particularly in the ears and the tail (data not shown). 
These pups were later confirmed to be triple transgenic using 
PCR and lacZ staining of ear biopsies (lacZ is expressed from 
the non-excised allele of the ZEG transgene). Although tTA 
has been reported to be toxic in mammalian cells (15), the 
triple transgenic embryos did not exhibit any obvious pheno-
type. All of the triple transgenic mice showed GFP expression 
at birth and in hematopoietic organs. Hematopoietic tissues, 
including the thymus and spleen, were also GFP fluorescent 
(Fig. 2F and H). In frozen sections of highly vascularized 
tissues, including the lung and kidney, blood vessel endothe-
lial cells also exhibited green fluorescence (data not shown). 
These results confirm that the Tie2‑tTA/tet-O-Cre transgenes 
mediate Cre excision in endothelial and hematopoietic cells.
Cre excision is delayed by maintenance on doxycycline and 
activated by doxycycline withdrawal. Once it was estab-
lished that the triple transgenic system produced reporter 
Figure 2. Measurement of Cre excision in the absence of tetracycline treatment. (A and B) Whole‑mount AP staining of (A) E10.5 control embryos and (B) E10.5 
Tie2-tTA/tet-O-Cre/ZAP embryos; (C and D) AP staining of sections of E11.5 Tie2-tTA/tet-O-Cre/ZAP embryos. Arrows indicate AP positive hematopoietic 
cells. (E‑H) EGFP fluorescence. (E) Bright field view of spleens from control and Tie2‑tTA/tet-O-Cre/ZEG mice and (F) the same spleens under GFP light. 
The spleen from a control mouse is dark, whilst the spleen from a triple transgenic mouse exhibits green fluorescence. (G) Bright field view of thymuses from 
control and Tie2-tTA/tet-O-Cre/ZEG mice and (H) the same spleens under GFP light. The thymus from a control mouse is dark, whilst the thymus from a 
Tie2-tTA/tet-O-Cre/ZEG mouse exhibitis green fluorescence. AP, alkaline phosphatase; DA, dorsal aorta; ACV, anterior cardinal vein; CA, cortical artery; HV, 
head vein; C, control mice; T, triple transgenic Tie2-tTA/tet-O-Cre/ZEG mice; EGFP, enhanced green fluorescence protein.
EXPERIMENTAL AND THERAPEUTIC MEDICINE  8:  1351-1356,  2014 1355
gene expression in endothelial and hematopoietic cells in 
the absence of tetracycline, it was then determined whether 
reporter gene expression would be inhibited in the presence 
of tetracycline. It was hypothesized that tetracycline would 
inhibit tTA activation of the tet-O-Cre transgene; thus, Cre 
would not be expressed, and consequently the AP and EGFP 
reporter genes would not be expressed (Fig. 1A).
Breeding pairs of tet-O-Cre males and Tie2-tTA/ZEG 
females were maintained on 0.1 mg/ml doxycycline supplied 
in the drinking water from the time they were mated. At this 
level, doxycycline, a tetracycline analogue, is sub-therapeutic 
but sufficient to repress tTA (23). Following doxycycline 
treatment, breeding pairs did not produce any pups exhibiting 
green fluorescence, although Tie2‑tTA/tet-O-Cre/ZEG triple 
transgenic pups (identified by PCR genotyping) were observed 
in a normal Mendelian ratio. The thymus, spleen, kidney and 
liver of these newborn triple transgenic pups did not show 
any GFP fluorescence, indicating that tTA was repressed by 
doxycycline.
In some litters, doxycycline was withdrawn two days 
after the pups were born and pups were sacrificed after 
28 days in order to determine whether Cre excision and 
subsequent EGFP expression could be obtained by postnatal 
doxycycline withdrawal (Fig. 1B). Mosaic expression of 
EGFP was observed in endothelial cells in various organs, 
as demonstrated by comparing immunostaining for EGFP 
and the endothelial marker PECAM‑1 staining in serial 
sections of liver (Fig. 3B and C). With removal of doxycy-
cline, Tie2-tTA/tet-O-Cre/ZEG triple transgenic thymus 
showed green fluorescence and EGFP+ cells were detected 
in the spleen and thymus using flow cytometry (Fig. 4B 
and D). Therefore, removal of doxycycline efficiently led to 
Cre expression and excision and consequent expression of the 
EGFP reporter.
Discussion
Recently, a number of studies have attempted to characterize 
the genes involved in pathological processes of adult vascu-
lature (24-26). The Cre conditional system combined with 
the inducible tTA system used in the present study enables 
the deletion of a gene or expression of a mutated gene at any 
time point during the lifespan of the mice. In particular, it 
allows studies of gene functions at stages of development 
after which deletion or misexpression is normally lethal. For 
example, deletion of the Notch1 receptor has been found to be 
embryonic lethal at E9.5, thus limiting the understanding of 
its role during early embryogenesis (3,6). Using this system, 
this problem may be overcome, and the Notch1 receptor can 
be deleted after E10.5 to study its potential function in adult 
angiogenesis, which has not been possible to investigate 
directly by gene targeting studies.
Figure 3. Measurement of Cre Excision in endothelial cells following tetracycline withdrawal. Breeding pairs were maintained on doxycycline, a tetracycline 
analogue, during pregnancy. Doxycycline was withdrawn the day after the litters were born and tissues were analyzed after 28 days. (A and B) EGFP immu-
nostaining of blood vessels from (A) a control mouse and (B) a Tie2-tTA/tet-O-Cre/ZEG mouse, which showed mosaic EGFP staining in endothelial cells. 
(C) Platelet‑endothelial cell adhesion molecule staining of a serial section of (B). EGFP, enhanced green fluorescence protein.Upper panel magnification, x100; 
lower panel magnification, X400.
Figure 4. Measurement of Cre excision in hematopoietic cells following tet-
racycline withdrawal. (A‑D) Fluorescence‑activated cell sorting analysis to 
measure enhanced green fluorescence protein expression in (A) the thymus 
from a control mouse; (B) the thymus from a Tie2-tTA/tet-O-Cre/ZEG 
mouse; (C) the spleen from a control mouse and (D) the spleen from a 
Tie2-tTA/tet-O-Cre/ZEG mouse.
  A   B
  C   D
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Unlike endothelial cells, which remain stable in the majority 
of adult organs, the hematopoietic system is a developing 
system (27,28). Mutation of a specific gene at different ages 
can result in different types of diseases or prognosis (29-31). 
By controlling the temporal activation of transgene expression, 
this inducible system may be useful in order to investigate gene 
function in hematopoiesis, leukemogenesis and lymphoma-
genesis, in particular disease-associated genes where genetic 
modification results in embryonic lethality.
In the present study, mosaic reporter gene expression 
occurred in endothelial and hematopoietic tissues in adult 
triple transgenic mice following doxycycline withdrawal. 
This may result from incomplete Cre activity, transgene 
silencing and/or reduced activation of the Tie2 promoter in 
adults. Mosaic expression has been observed in the majority 
of tetracycline-regulated models and also in other induc-
ible systems (20,32). However, gene functional studies can 
be conducted by comparison with appropriate controls and 
quantitative studies may be achieved through a variety of 
techniques.
In conclusion, it was demonstrated in the present study 
that a tetracycline-regulated Cre/loxP system may be used 
to conditionally express transgenes in endothelial and 
hematopoietic cells. The combination of the Cre/loxP and 
tetracycline-inducible systems to activate transgene expres-
sion can be used in other tissues by incorporating different 
promoters to drive the expression of tTA or rtTA (17,32). The 
application of this system may improve our ability to bypass 
embryonic lethal phenotypes and study gene function in adult 
mice. Furthermore, it may provide valuable animal models for 
therapeutic development.
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